文献速递重症综合管理与镇静镇痛心脑血管急症

心脏手术限制性与开放性红细胞输注策略比较

Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery.
PubMed 文献 · N Engl J Med · 2017-11-12
一句话结论心脏手术中高危死亡风险患者,限制性输血策略(血红蛋白<7.5 g/dL)在死亡、心梗、卒中或新发透析依赖肾衰竭复合终点上不劣于开放性策略,且输血更少。

TRICS III 多中心、开放标签、非劣效性随机试验纳入 5243 例接受心脏手术且 EuroSCORE I≥6 的成人。限制性策略为血红蛋白<7.5 g/dL 时输血(从麻醉诱导开始),开放性策略为手术室或 ICU 内血红蛋白<9.5 g/dL、非 ICU 病房<8.5 g/dL 时输血。主要复合终点(全因死亡、心肌梗死、卒中或新发透析依赖肾衰竭,至出院或第 28 天)限制性组 11.4% vs 开放性组 12.5%(绝对风险差 -1.11 个百分点,95%CI -2.93 至 0.72;OR 0.90,95%CI 0.76 至 1.07;非劣效 P<0.001)。限制性组输血率 52.3% vs 72.6%(OR 0.41,95%CI 0.37 至 0.47)。

要点

  • 心脏手术且 EuroSCORE I≥6 的成人,限制性输血阈值(血红蛋白<7.5 g/dL,从麻醉诱导开始)在主要复合终点上非劣于开放性阈值。
  • 主要复合终点:限制性组 11.4% vs 开放性组 12.5%,绝对风险差 -1.11 个百分点(95%CI -2.93 至 0.72),OR 0.90(95%CI 0.76 至 1.07),非劣效 P<0.001。
  • 全因死亡:限制性组 3.0% vs 开放性组 3.6%,OR 0.85(95%CI 0.62 至 1.16)。
  • 红细胞输注率:限制性组 52.3% vs 开放性组 72.6%,OR 0.41(95%CI 0.37 至 0.47)。
  • 其他次要结局两组间无显著差异。

适用人群与场景

  • 接受心脏手术的成人,EuroSCORE I≥6(量表 0–47 分,分数越高心脏手术后死亡风险越高)。

诊断标准与关键阈值

  • 限制性输血阈值:血红蛋白<7.5 g/dL 时输血,从麻醉诱导开始。
  • 开放性输血阈值:手术室或 ICU 内血红蛋白<9.5 g/dL 时输血,非 ICU 病房血红蛋白<8.5 g/dL 时输血。

处置流程与药物剂量

  • 限制性策略组:血红蛋白<7.5 g/dL 时输注红细胞,从麻醉诱导开始。
  • 开放性策略组:手术室或 ICU 内血红蛋白<9.5 g/dL 时输注红细胞,非 ICU 病房血红蛋白<8.5 g/dL 时输注红细胞。

研究设计与关键结果

  • 多中心、开放标签、非劣效性随机试验,纳入 5243 例接受心脏手术且 EuroSCORE I≥6 的成人,随机分为限制性输血阈值组或开放性输血阈值组。
  • 主要复合终点(全因死亡、心肌梗死、卒中或新发透析依赖肾衰竭,至出院或第 28 天):限制性组 11.4% vs 开放性组 12.5%,绝对风险差 -1.11 个百分点(95%CI -2.93 至 0.72),OR 0.90(95%CI 0.76 至 1.07),非劣效 P<0.001。
  • 全因死亡:限制性组 3.0% vs 开放性组 3.6%,OR 0.85(95%CI 0.62 至 1.16)。
  • 红细胞输注:限制性组 52.3% vs 开放性组 72.6%,OR 0.41(95%CI 0.37 至 0.47)。
  • 其他次要结局两组间无显著差异。

证据类型、等级与局限

  • 证据类型:多中心、开放标签、非劣效性随机对照试验。

对床旁实践的改变

  • 对于接受心脏手术且 EuroSCORE I≥6 的成人,采用限制性红细胞输注阈值(血红蛋白<7.5 g/dL,从麻醉诱导开始)在主要复合终点上不劣于开放性阈值,且红细胞输注更少。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The effect of a restrictive versus liberal red-cell transfusion strategy on clinical outcomes in patients undergoing cardiac surgery remains unclear.

METHODS: In this multicenter, open-label, noninferiority trial, we randomly assigned 5243 adults undergoing cardiac surgery who had a European System for Cardiac Operative Risk Evaluation (EuroSCORE) I of 6 or more (on a scale from 0 to 47, with higher scores indicating a higher risk of death after cardiac surgery) to a restrictive red-cell transfusion threshold (transfuse if hemoglobin level was <7.5 g per deciliter, starting from induction of anesthesia) or a liberal red-cell transfusion threshold (transfuse if hemoglobin level was <9.5 g per deciliter in the operating room or intensive care unit [ICU] or was <8.5 g per deciliter in the non-ICU ward). The primary composite outcome was death from any cause, myocardial infarction, stroke, or new-onset renal failure with dialysis by hospital discharge or by day 28, whichever came first. Secondary outcomes included red-cell transfusion and other clinical outcomes.

RESULTS: The primary outcome occurred in 11.4% of the patients in the restrictive-threshold group, as compared with 12.5% of those in the liberal-threshold group (absolute risk difference, -1.11 percentage points; 95% confidence interval [CI], -2.93 to 0.72; odds ratio, 0.90; 95% CI, 0.76 to 1.07; P<0.001 for noninferiority). Mortality was 3.0% in the restrictive-threshold group and 3.6% in the liberal-threshold group (odds ratio, 0.85; 95% CI, 0.62 to 1.16). Red-cell transfusion occurred in 52.3% of the patients in the restrictive-threshold group, as compared with 72.6% of those in the liberal-threshold group (odds ratio, 0.41; 95% CI, 0.37 to 0.47). There were no significant between-group differences with regard to the other secondary outcomes.

CONCLUSIONS: In patients undergoing cardiac surgery who were at moderate-to-high risk for death, a restrictive strategy regarding red-cell transfusion was noninferior to a liberal strategy with respect to the composite outcome of death from any cause, myocardial infarction, stroke, or new-onset renal failure with dialysis, with less blood transfused. (Funded by the Canadian Institutes of Health Research and others; TRICS III ClinicalTrials.gov number, NCT02042898 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Mazer CD, Whitlock RP, Fergusson DA, et al. Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery. N Engl J Med. 2017. PMID: 29130845. doi:10.1056/NEJMoa1711818

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。